MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/j.jcrs.0000000000002040

Медицинская библиотека · Journal of cataract and refractive surgery · 2026

One-year clinical outcomes of theranostic-guided transepithelial corneal UV therapy for progressive keratoconus.

Lombardo Marco, Serrao Sebastiano, Mencucci Rita, Buzzi Matilde, Fegatelli Danilo Alunni, Vestri Annarita, Lombardo Giuseppe

СтатьяПеревод в очереди

Аннотация

PURPOSE: To evaluate the efficacy of theranostic-guided transepithelial corneal UV therapy in treatment of progressive keratoconus and the association between theranostic imaging biomarkers and 1-year outcomes.

SETTING

Careggi hospital and Studio Italiano di Oftalmologia, Italy.

DESIGN

Real-world evidence case series.

METHODS

Fifty-five consecutive patients (55 eyes) were treated using a theranostic UV medical device. A 0.22% riboflavin ophthalmic solution was applied onto the cornea with intact epithelium for 20 minutes followed by UV irradiation at 10 mW/cm2 for 9 minutes in all cases. The theranostic UV device generated intraoperative imaging biomarkers, the riboflavin score and theranostic score, quantifying corneal riboflavin concentration and photoactivation efficacy, respectively. The device guided surgeons in completing treatment based on real-time biomarker monitoring.

RESULTS

Fifty-four patients (54 eyes) completed 1-year follow-up. Treatment was safe and effective, with the predefined riboflavin score (>0.4 d.u.) and theranostic score (≥0.6 d.u.) thresholds accurately identifying Kmax flattening at 1-year in 93% of cases. Additional riboflavin was required in 21% of eyes (n=12), and 15% additional UV energy was required in 5% of eyes (n=3) to reach the theranostic thresholds, thus precisely adjusting the required dose of riboflavin and UV light for each eye. Mean Kmax decreased by -1.5±1.5 D (P < 0.001) with clinically significant improvements in both uncorrected and corrected distance visual acuity (P < 0.001).

CONCLUSION

Theranostic-guided corneal UV therapy enables patient-specific modulation of riboflavin dosing and UV-A delivery, optimizing corneal flattening and visual outcomes while minimizing the risk of treatment failure under epithelium-on conditions in progressive keratoconus.

Для цитирования: Lombardo Marco, Serrao Sebastiano, Mencucci Rita, Buzzi Matilde, Fegatelli Danilo Alunni, Vestri Annarita, Lombardo Giuseppe. One-year clinical outcomes of theranostic-guided transepithelial corneal UV therapy for progressive keratoconus.. Journal of cataract and refractive surgery. 2026. DOI: 10.1097/j.jcrs.0000000000002040.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.